Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Best Peptides for Weight Loss

Best Peptides for Weight Loss

The most effective peptides for fat loss and appetite suppression, from FDA-approved GLP-1 agonists to targeted fat-burning fragments.

Expert Protocols

Reviewed protocols from researchers, physicians, and creators who have publicly disclosed their dosing.

Ranked list

1

Tirzepatide

Weight LossHalf-life: ~5 days2.5 mg-15 mg
FDA Label(n=2,539 (SURMOUNT-1))

The most powerful weight loss peptide available. Tirzepatide targets both GIP and GLP-1 receptors, producing up to 20.9% body weight loss in clinical trials, more than any single-agonist peptide (PMID 35658024).

Pros
  • FDA-approved (Mounjaro/Zepbound)
  • Superior weight loss vs semaglutide in head-to-head trials (PMID 40353578)
  • Dual mechanism (GIP + GLP-1)
  • Once-weekly dosing
Cons
  • GI side effects during titration (nausea, diarrhea)
  • Expensive
  • Weight regain after discontinuation
2

Semaglutide

Weight LossHalf-life: ~7 days250 mcg-2.4 mg
FDA Label(n=1,961 (STEP 1))

The most well-known GLP-1 agonist (Ozempic/Wegovy). Proven 14.9% mean body weight loss in STEP 1, with the most extensive long-term safety data of any weight loss peptide (PMID 33567185).

Pros
  • FDA-approved with extensive safety data
  • Proven cardiovascular benefits (PMID 37952131)
  • Once-weekly dosing
  • Most accessible GLP-1 option
Cons
  • Less effective than tirzepatide in trials
  • GI side effects common during titration
  • Weight regain after stopping
3

Orforglipron

Weight LossHalf-life: ~29-49 hours0.8 mg-17.2 mg
FDA Label(n=4,740 (ATTAIN-1 and ATTAIN-2))

The first oral non-peptide GLP-1 agonist (brand name Foundayo). FDA-approved in April 2026. Unlike every other GLP-1 drug, it's a small-molecule pill you take once daily with no food or water restrictions. The ATTAIN-1 trial showed 11.2% body weight loss at the top dose (PMID 40960239), and it beat oral semaglutide head-to-head in the ACHIEVE-3 trial (PMID 41765029).

Pros
  • FDA-approved, no injections needed
  • No food, water, or fasting restrictions (unlike oral semaglutide)
  • Take it any time of day
  • Self-pay price of $149/month
Cons
  • Less weight loss than injectable tirzepatide or semaglutide
  • Higher GI side effect discontinuation rate than injectables
  • Requires daily dosing (not weekly)
4

Retatrutide

Weight LossHalf-life: ~6 days1 mg-12 mg
Clinical Trial

The first triple-agonist (GLP-1 + GIP + glucagon). In the phase 3 TRIUMPH-1 trial, 12 mg produced 25.0% weight loss at 80 weeks (PMID 42814954). It is not yet FDA-approved. The glucagon component also reduces liver fat.

Pros
  • 25.0% weight loss at 80 weeks in phase 3 (TRIUMPH-1)
  • Triple mechanism attacks fat from 3 angles
  • Reduces liver fat significantly
  • Once-weekly dosing
Cons
  • Still investigational, not yet FDA-approved
  • Limited long-term safety data
  • GI side effects during titration
5

AOD-9604

Weight LossHalf-life: Unknown (no human data; about three minutes after an IV dose in pigs)200 mcg-500 mcg
Community Consensus

A targeted fat-burning fragment of HGH (amino acids 177-191). Unlike GLP-1 agonists, it directly stimulates lipolysis without affecting appetite, blood sugar, or growth. A different mechanism entirely: it can be paired with GLP-1 drugs for combined fat loss.

Pros
  • Directly targets fat metabolism
  • No effect on blood sugar or insulin
  • GRAS safety status
  • Can be combined with GLP-1 agonists
Cons
  • Much weaker weight loss than GLP-1 agonists
  • Requires daily dosing on empty stomach
  • Phase 2 data only: limited clinical evidence

Head-to-Head Comparisons

See how these ranked peptides compare side by side.

Need to calculate a dose for any peptide? Use the dosage calculator

How We Ranked These

Ranked by clinical trial weight loss data, FDA approval status, mechanism breadth, and real-world accessibility. FDA-approved options rank above investigational ones. GLP-1 agonists lead because they have the strongest evidence base.

Beginner Recommendation

Start with Semaglutide for proven, accessible weight loss. Prefer Orforglipron if you want an oral option with no needles. Tirzepatide for maximum results.

View Weight Loss Stack →
Explore all Weight Loss peptides

Frequently Asked Questions

Retatrutide reached 25.0% at 80 weeks on 12 mg in the phase 3 TRIUMPH-1 trial (PMID 42814954), but it is not yet approved. Among approved options, Tirzepatide (20.9% in SURMOUNT-1) outperforms Semaglutide (14.9% in STEP 1). Two oral options are approved. Orforglipron reached 11.2% at 72 weeks in ATTAIN-1 (PMID 40960239); oral semaglutide 25 mg reached 13.6% at 64 weeks in OASIS 4 (PMID 40934115). No obesity trial has compared the two head to head. ACHIEVE-3 compared orforglipron with oral semaglutide 7 and 14 mg in type 2 diabetes on HbA1c, not the 25 mg weight-loss dose (PMID 41765029).

Yes, Orforglipron (Foundayo) is an FDA-approved oral GLP-1 pill. Take once daily, no food or water restrictions. It's less potent than injectable options but avoids needles entirely.

You can combine a GLP-1 agonist (Semaglutide or Tirzepatide) with AOD-9604, which targets fat through a different pathway. Do NOT stack two GLP-1 agonists together.

Studies show significant weight regain after stopping GLP-1 agonists (PMID 35441470). Many users transition to a maintenance dose rather than stopping completely. AOD-9604 may help maintain results.
5 peptides ranked